ATARA BIOTHERAPEUTICS INC (ATRA) Stock News
NASDAQ:ATRA - Nasdaq - US0465132068 - Common Stock - Currency: USD
ATRA Latest News, Press Relases and Analysis
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws
/PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA). Such...
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA). Such...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA). Such...
ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA). Such...
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip
CEO Cokey Nguyen expressed confidence in resolving the issue, expecting resubmission and potential approval within six months of addressing the manufacturing compliance concerns.
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)
ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Atara Biotherapeutics (NASDAQ:ATRA) just reported results for the second quarte...
Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Atara Biotherapeutics Announces $36 Million Registered Direct Offering
ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q2 2024
ATRA stock results show that Atara Biotherapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
